Sugi Predict

Sugi Predict / Compounds / SCHEMBL950223

SCHEMBL950223

SCHEMBL950223

O=C(O)CCCCNC(=O)c1ccccc1

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.83
▸ HDAC6 Q9UBN7 8/20 0.71
▸ HDAC1 Q13547 7/20 0.71
▸ HDAC2 Q92769 7/20 0.71
▸ HDAC3 O15379 6/20 0.71
▸ HDAC8 Q9BY41 6/20 0.71
▸ HDAC4 P56524 5/20 0.71
▸ HDAC7 Q8WUI4 5/20 0.71
▸ HDAC10 Q969S8 5/20 0.71
▸ HDAC11 Q96DB2 5/20 0.71
▸ HDAC9 Q9UKV0 5/20 0.71
▸ HDAC5 Q9UQL6 5/20 0.71
▸ CYP1A2 P05177 1/20 0.71
▸ CYP2C9 P11712 1/20 0.71
▸ CYP2C19 P33261 1/20 0.71
▸ LMNA P02545 1/20 0.68
▸ NAAA Q02083 1/20 0.67
▸ NPC1 O15118 1/20 0.64
▸ RAB9A P51151 1/20 0.64
▸ ALDH1A1 P00352 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10659200 0.98 MAPK1 (0.86) MAPK1HDAC6HDAC1HDAC2HDAC3
SCHEMBL10865398 0.98 MAPK1 (0.86) MAPK1HDAC6HDAC1HDAC2HDAC3
SCHEMBL5655215 0.98 MAPK1 (0.86) MAPK1HDAC6HDAC1HDAC2HDAC3
SCHEMBL1231651 0.98 MAPK1 (0.86) MAPK1HDAC6HDAC1HDAC2HDAC3
SCHEMBL2033165 0.94 MAPK1 (0.73) MAPK1HDAC6HDAC1HDAC2HDAC3
SCHEMBL8770694 0.92 MAPK1 (0.76) MAPK1HDAC6HDAC1HDAC2HDAC3
SCHEMBL3081575 0.92 MAPK1 (0.81) MAPK1HDAC6HDAC1HDAC2HDAC3
SCHEMBL3596135 0.92 MAPK1 (0.81) MAPK1HDAC6HDAC1HDAC2HDAC3
SCHEMBL27339421 0.92 MAPK1 (0.76) MAPK1HDAC6HDAC1HDAC2HDAC3
SCHEMBL428355 0.91 MAPK1 (1.00) MAPK1HDAC6HDAC1HDAC2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119233657-A Perovskite solar cell, preparation method thereof and photovoltaic module 天合光能股份有限公司 2024-12-31 — — CN claimed
CN-1732161-A 1,3-diamino-2-hydroxypropane pro-drug derivatives ELAN PHARM INC (US) 2006-02-08 — — CN claimed
CN-1036832-C Composition containing a penem or carbapenem artibiotic and the use of the same SANKYO CO (JP) 1997-12-31 — — CN claimed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 — — EP claimed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 — — US claimed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 — — EP claimed
CN-86107574-A Compositions containing penem or carbapenem antibiotics and their use — 1987-05-20 — — CN claimed
CN-119233657-A Perovskite solar cell, preparation method thereof and photovoltaic module 天合光能股份有限公司 2024-12-31 — — CN disclosed
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-13 — — US disclosed
US-20070004736-A1 Imidazole derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-04 — — US disclosed
US-7115741-B2 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds ALEXION PHARMACEUTICALS, INC. 2006-10-03 — — US disclosed
CN-1732161-A 1,3-diamino-2-hydroxypropane pro-drug derivatives ELAN PHARM INC (US) 2006-02-08 — — CN disclosed
EP-1564213-A1 IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-08-17 — — EP disclosed
US-6005034-A POLYMER MELTS OF ETHYLENE-PROPYLENE COPOLYMERS CHISSO CORPOATION (JP) 1999-12-21 — — US disclosed
US-5716998-A PARTICLES COMPRISING POLYPROPYLENE RESIN AND DIAMIDE COMPOUND AS BETA-FORM NUCLEATING AGENT KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1998-02-10 — — US disclosed
EP-0790262-A1 PROPYLENE-ETHYLENE COPOLYMER COMPOSITIONS AND PROCESS FOR THE PRODUCTION THEREOF CHISSO CORPORATION (JP) 1997-08-20 — — EP disclosed
EP-0790275-A1 PREFOAMED PARTICLES OF POLYPROPYLENE RESIN AND PROCESS FOR PRODUCING THE SAME KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1997-08-20 — — EP disclosed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 — — EP disclosed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 — — US disclosed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004736-A1 Imidazole derivative, process for producing the same, and use HRH4, F2, HRH2 MAPK1 1855/4885HDAC6 743/4885HDAC1 40/4885
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE F2, H1-3, CYC1 MAPK1 1718/4885HDAC6 662/4885HDAC1 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.